Canada Markets open in 2 hrs 10 mins

Eli Lilly and Company (LLY)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
324.71+0.48 (+0.15%)
At close: 04:03PM EDT
325.00 +0.07 (+0.02%)
After hours: 07:59PM EDT
Sign in to post a message.
  • G
    Glen
    LLY has the only effective drug therapy for obesity tirzipatide, better than gastric sleeve, better than lap band. It is given subcutaneously, weekly and no major side effects. It is the only effective obesity med and is taken lifelong. This will be 10 times over the best selling medication in history. In addition it will PREVENT diabetes, hypertension and arthritis of knees and hips……will eventually have 5 indications. Never before seen in medicine. It may also prevent heart disease by preventing obesity.
  • B
    Bichard
    Ready to get in on some secret growth stocks? These 5 stocks could grow 391% EACH! Don’t delay, get you FREE report TODAY from the experts at (http://winningstocks.club)
  • G
    Glen
    Lly has the only effective weight loss drug- tirzepatide. It will prevent diabetes, heart disease and arthritis of hips and knees. These are all caused by obesity. This will be 10 times over the best selling drug of all time.
  • T
    TruthWillBeFound
    From 288 to 325 in 5 days! Wonder what the next 30 days will bring?
  • C
    Crecy
    So this is the move I posted about 2weeks ago
  • M
    Market Wizards
  • B
    Burrill
    It’s my personal belief that LLY should acquire SAVA while it’s cheap.
  • J
    Justin
    Polio in the UK again after 50 years, good for this company
  • G
    Glen
    Preventing ,treating obesity, prevents most human chronic diseases.
  • R
    Rick
    Hope to sell Lilly this year to buy a new home. I will miss owning the stock as it has been a great investment. I'm a 30+ year long and invested the dividend the entire time. I also put in an occasional extra $1 or $2k every couple of years if I could afford it. Now for what has been a modest initial investment of 30k along with the dividend and extra small add on the stock has grown to over 600k, with which I will buy a new home. Not bad for a poor boy who didn't graduate college or received an inheritance to speak of. Thank you Lilly for being a good, solid company that saves lives, promotes health and makes investors well off.
  • T
    Tom
    43 pe....too high
  • e
    eric
    when will they split?
  • A
    Anonymous
    I know healthcare/pharma isn't impacted by economic slowdowns, the same way as other sectors, but valuation has to be taken into account. Staples stocks were safe until last week. I know pharma stocks don't have that same economic concern. I know LLY deserves a higher valuation based on it's growth, but still, are any of you who own or are looking to own LLY have any valuation concerns? I don't want to buy the weak sectors, which are pretty much all of them, outside of Energy, Healthcare, and Utilities, but I don't want to buy into a hot sector at the top. Just seems like LLY is doing great. But if the market wants to int can punish healthcare/LLY too. With LLY's valuation it could really go down. Seems it's had too much good news and good fundamentals to drop, so far.
  • G
    Glen
    LLY will make many big pharma obsolete!
  • R
    Randy
    the highest $540, and the lowest $72. something is cooking🕵️‍♂️
  • J
    John
    I feel LLY will show some great numbers and statistics about some of their studies / drugs in the pipeline this Monday at the conference. I am buying a lot today in anticipation of a nice rise in share price of LLY on Monday.
  • W
    What
    Baldness cure
  • A
    Ah Lek
    DUNDEE CORPORATION (DC-A.TO), TAURX PHARMACEUTICALS LTD., ANNOUNCES MOVE TOWARD REGULATORY SUBMISSION FOLLOWING INITIAL DATA FROM LUCIDITY TRIAL

    Dundee Corp. portfolio holding TauRx Pharmaceuticals Ltd. unveiled initial data from the randomized portion of its widely followed phase 3 clinical trial, Lucidity (NCT03446001). Dundee holds 1,015,008 shares in TauRx.

    TauRx announcement highlights:

    Lucidity data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research.
    Safety profile is favourable and consistent with previous HMTM studies.
    TauRx will now pursue regulatory submission and coverage for HMTM.

    TauRx reports its lead investigative oral drug, HMTM, was tested in 598 people afflicted with Alzheimer's. TauRx announced participants of the 12-month blinded phase of the study have moved to an additional one-year open label phase.

    According to TauRx's announcement, Prof. Claude Wischik, executive chairman and co-founder of TauRx, commented: "The output indicates that participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer's based on published research. This was seen for both cognitive and functional end points across a broad range of severity from mild cognitive impairment (MCI) to moderate Alzheimer's. Importantly, the safety profile is favourable and consistent with previous studies."

    TauRx advises its data analysis is continuing and will be reported at a later date. Meanwhile, TauRx will be providing an update on their progress at the 35th Global Conference of Alzheimer's Disease on June 9, 2022.
  • C
    Crecy
    Looking for this to move higher by next week.
  • B
    Broadway Brokers
    One of the only large cap biotech stock to be up on their YTD chart.